Nucleo describes itself as the first agentic platform for oncology, helping oncologists and radiologists extract insights from CT scans to support tumor characterization and treatment planning. The platform automates key oncological metrics including sarcopenia detection, body composition assessment, lesion volume measurement and lesion classification. Validation studies cited by the company show 98% agreement between Nucleo and medical experts, with segmentation up to 2,500x faster than manual workflows. Hospitals it works with include Stanford Hospital, Cedars-Sinai, UCI Health and Weill Cornell. Nucleo is part of Y Combinator's Fall 2025 batch.